Learning Objectives:

  1. Review the diagnosis, evaluation, and treatment of osteoporosis.
  2. Evaluate the evidence for use of osteoclast inhibitors in early breast cancer and review current guidelines.
  3. Understand the risks of bone loss and vertebral fractures after denosumab discontinuation and discuss sequential use of bisphosphonates to prevent these complications.
Session date: 
11/11/2019 - 12:00pm to 1:00pm CST
900 East 57th Street
KCBD Auditorium 1103
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Laura T. Dickens, MD